NLRP3 and triple-A syndrome: Treatment with colchicine for 80 days significantly reduced caspase-1 activity, a marker of NLRP3 inflammasome activity; however, this did not result in decreased aortic IL-1β concentration and did not significantly reduce AAA growth or rupture.